Skip to main content

Table 2 Follow-up and final disposition of subjects a

From: A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways

 

Women, n

Men, n

Total subjects

1,390

1,158

CD diagnosed by histology before enrolment

0

1

Abnormal composite TG2/DGP IgA/IgG, and TG2 IgA, or DGP IgA or IgG

51

56

Findings diagnostic/supportive of untreated CD

  

 Histological diagnosis: Intestinal villous atrophy, crypt hyperplasia, and IELs

  

  Prompted by current study, 2010

6

4

  During standard medical care between 2004 and 2009

4

2

 Serological diagnosis: confirmation of multiple CD serological abnormalities

  

  No supporting histological evidence obtained

2

3

  Treating doctor excluded CD because patient was asymptomatic

0

2

Findings equivocal for CD

  

 Intestinal IELs +/− mild focal villous atrophy, or villous atrophy and crypt hyperplasia without IELs

0

3

Findings excluded/were not supportive of CD

  

 Normal intestinal histology without serological testing

2

5

 Serological exclusion: CD serological abnormalities not replicated

7

8

 Genotyping exclusion: testing for HLA DQ2.5/8/2.2 negative

0

1

Follow-up not possible or not undertaken

  

 Treating doctor did not investigate further as subject asymptomatic and/or performed blood tests unrelated to CD

1

5

 Subject deceased and CD not diagnosed pre-mortem

8

5

 Subject declined follow-up medical review

16

11

 Subject could not be contacted; lost to follow-up

5

7

CD cases estimated by serogenetic modeling, range

12 to 26

12 to 16

Lower 95% CI for CD cases based on TG2+ EMA+

11

12

  1. Abbreviations: CD, celiac disease; DGP, Deamidated gliadin-derived peptide; EMA, endomysial antibody; HLA, human leukocyte antigen; IEL, Intra-epithelial lymphocyte; Ig, immunoglobulin; TG, transglutaminase.
  2. aData are n, unless otherwise stated.